thrombin human

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
thrombin human
Generic name
THROMBIN HUMAN
Manufacturer
Ethicon, Inc
Product type
PLASMA DERIVATIVE
SPL set ID
02edcd44-1c26-45f1-a75c-f1f639d1956e
SPL ID
374e14e3-6a79-c213-e063-6394a90af910
Version
12
Effective date
2025-06-11
Source export date
2026-11-13
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:32:51
Harmonized routes table
Harmonized routes
TOPICAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Potential risk of thrombosis if absorbed systemically ( 5.1 ) . May carry a risk of transmitting infectious agents such as viruses and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite manufacturing steps designed to reduce the risk of viral transmission ( 5.2 ) . Hypersensitivity reactions, including anaphylaxis, may occur ( 5.1 ) . 5.1 Thrombosis There is a risk of thrombosis if absorbed systemically. Apply topically only. 5.2 Anaphylactic/Hypersensitivity Reactions Anaphylactic reactions may occur in rare cases. No adverse events of this type were reported during the conduct of the clinical trials. Severe hypotensive reactions require immediate intervention using current principles of shock therapy. 5.3 Transmission of Infectious Agents Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of transmitting an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections and by inactivating and removing certain viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions during clinical trial (reported in at least 2% of subjects treated with EVITHROM™) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count. The most common adverse reactions (incidence 2%) were prolonged activated partial thromboplastin time, increased INR, decreased lymphocyte count, prolonged prothrombin time and increased neutrophil count ( 6 ). None of the patients treated with EVITHROM™ developed antibodies to human thrombin or to human Factor V/Va. The clinical significance of these findings is unknown ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact ETHICON Customer Support Center at (877) 384-4266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In a multicenter, prospective, controlled, randomized, double-blinded clinical trial of 305 subjects where EVITHROM™ (n=153) was compared with bovine thrombin (n=152), occurrence of adverse events was not statistically different between the two groups. Overall, adverse events occurred in similar proportions of subjects in the two groups (see Table 1 ). No clinically significant differences were seen in age (<65 years, >65 years) or gender subgroup analyses of adverse events. At least one serious adverse event (SAE) was reported for 26/153 (17%) subjects treated with human thrombin and 17/152 (11%) subjects treated with bovine thrombin. The SAEs reported were associated with post-surgical complications (e.g. wound infection 3/153 for EVITHROM™ and 2/152 for bovine thrombin) and the medical condition of the subject and were not considered related to study drug. Two subjects (1.3%) in EVITHROM™ group experienced a treatment emergent severe adverse event: respiratory arrest and post-procedural hematoma (in one subject) and extradural hematoma. Three subjects in the bovine thrombin group experienced a treatment emergent severe adverse event: hyperhidrosis, pyrexia and post-procedural hematoma. No deaths were reported during the study period. Viral serology was not monitored during the trial with EVITHROM™. However, no adverse events indicative of infection with transfusion-transmissible agents were reported. Table 1: Incidence of subjects with related adverse events reported in at least 2% of subjects treated with either human or bovine thrombin Thrombin Type System Organ Class/Adverse Event EVITHROM™ (n=153) Bovine (n=152) Total (n=305) Investigations 11 (7.2%) 14 (9.2%) 25 (8.2%) Activated partial thromboplastin time increased 4 (2.6%) 8 (5.3%) 12 (3.9%) International normalized ratio increased 4 (2.6%) 5 (3.3%) 9 (3.0%) Lymphocyte count decreased 4 (2.6%) 2 (1.3%) 6 (2.0%) Prothrombin time prolonged 4 (2.6%) 8 (5.3%) 12 (3.9%) Neutrophil count increased 3 (2.0%) 2 (1.3%) 5 (1.6%) Skin and Subcutaneous Tissue Disorders 1 (0.7%) 3 (2.0%) 4 (1.3%) Pruritus 1 (0.7%) 3 (2.0%) 4 (1.3%) General Disorders and Administration Site Conditions 0 3 (2.0%) 3 (1.0%) Immunogenicity In the clinical study, serum samples were collected at baseline and at 5 weeks post-surgery for evaluation of antibodies to bovine thrombin, bovine Factor V/Va, human thrombin, and human Factor V/Va. Samples were collected at both time points for 81.3% of the subjects. The ELISA data were adjudicated by a panel of experts blinded to treatment assignment. After reviewing all data, the panel used an algorithm for assigning outcomes for each antigen: seroconversion negative or seroconversion positive. The protocol did not specify any comparative analysis for immunogenicity data, only descriptive statistics. The adjudicated results show that 3.3% of the subjects treated with EVITHROM™ (frozen formulation) developed antibodies to any of the four antigens, compared to 12.7% of the subjects developing antibodies in the control group (bovine thrombin). 7.9% of the subjects treated with bovine thrombin (control group) developed antibodies to bovine thrombin and 9.5% of these subjects developed antibodies to bovine Factor V/Va. A few control subjects had antibodies that cross-reacted with human thrombin, but none had antibodies that crossreacted with human Factor V/Va. None of the patients treated with EVITHROM™ developed detectable antibodies to human thrombin or to human Factor V/Va. The detection of antibody formation is highly dependent upon the sensitivity and specificity of the assay. The observed incidence of a positive signal in an assay may be influenced by several factors including timing of sampling, sample handling, concomitant medications, or underlying disease. Therefore, direct comparison of incidence of antibody development to human thrombin, bovine thrombin, human Factor V/Va or bovine Factor V/Va following administration of EVITHROM™ with incidence of antibody development following administration of other products may be misleading and the clinical significance of these findings is unknown. 6.2 Post Marketing Experience No adverse reactions have been identified from spontaneous post-marketing reports.

adverse reactions table

<table width="75%" ID="table1"><caption>Table 1: Incidence of subjects with related adverse events reported in at least 2% of subjects treated with either human or bovine thrombin</caption><col width="55%" align="left" valign="top"/><col width="15%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><col width="15%" align="center" valign="top"/><thead><tr styleCode="Botrule"><th styleCode="Lrule Rrule"/><th colspan="2" styleCode="Rrule">Thrombin Type</th><th styleCode="Rrule"/></tr><tr><th styleCode="Lrule Rrule" valign="bottom">System Organ Class/Adverse Event</th><th align="center" styleCode="Rrule">EVITHROM&#x2122; (n=153) </th><th styleCode="Rrule">Bovine (n=152) </th><th styleCode="Rrule">Total (n=305) </th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Investigations</content></td><td styleCode="Rrule"><content styleCode="bold">11 (7.2%)</content></td><td styleCode="Rrule"><content styleCode="bold">14 (9.2%)</content></td><td styleCode="Rrule"><content styleCode="bold">25 (8.2%)</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> Activated partial thromboplastin time increased</td><td styleCode="Rrule">4 (2.6%)</td><td styleCode="Rrule">8 (5.3%)</td><td styleCode="Rrule">12 (3.9%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> International normalized ratio increased</td><td styleCode="Rrule">4 (2.6%)</td><td styleCode="Rrule">5 (3.3%)</td><td styleCode="Rrule">9 (3.0%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> Lymphocyte count decreased</td><td styleCode="Rrule">4 (2.6%)</td><td styleCode="Rrule">2 (1.3%)</td><td styleCode="Rrule">6 (2.0%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> Prothrombin time prolonged</td><td styleCode="Rrule">4 (2.6%)</td><td styleCode="Rrule">8 (5.3%)</td><td styleCode="Rrule">12 (3.9%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> Neutrophil count increased</td><td styleCode="Rrule">3 (2.0%)</td><td styleCode="Rrule">2 (1.3%)</td><td styleCode="Rrule">5 (1.6%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> </td><td styleCode="Rrule"/><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content></td><td styleCode="Rrule"><content styleCode="bold">1 (0.7%)</content></td><td styleCode="Rrule"><content styleCode="bold">3 (2.0%)</content></td><td styleCode="Rrule"><content styleCode="bold">4 (1.3%)</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> Pruritus</td><td styleCode="Rrule">1 (0.7%)</td><td styleCode="Rrule">3 (2.0%)</td><td styleCode="Rrule">4 (1.3%)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"> </td><td styleCode="Rrule"/><td styleCode="Rrule"/><td styleCode="Rrule"/></tr><tr><td styleCode="Lrule Rrule"><content styleCode="bold">General Disorders and Administration Site Conditions</content></td><td styleCode="Rrule"><content styleCode="bold">0</content></td><td styleCode="Rrule"><content styleCode="bold">3 (2.0%)</content></td><td styleCode="Rrule"><content styleCode="bold">3 (1.0%)</content></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.